![](https://investorshub.advfn.com/uicon/61569.png?cb=1621345219)
Wednesday, April 20, 2022 3:26:25 PM
CUBT has an impressive pipeline with a NIH clinical trial for the macular degeneration just announced. Unfortunately, in a quiet period, the PR came out as a whisper.
Looking forward to that Quiet Period ending soon so there can be a little more noise about what the company is doing:
Infectious Diseases
IMT505 Rabies (1)
Priority Review Voucher (PRV) Eligible
Infectious Diseases
COVID Vaccine with IMT504 Adjuvant
COVID 19 in Kidney Failure Patients (2)
Oncology
CUBT906- CD56 Monoclonal Antibody ADC Glioblastoma (2)
Degenerative Eye Disease
Metformin Reformulation
Age-Related Macular Degeneration (1)
(1) Each of these therapeutics have undergone certain toxicology and pharmacokinetics animal studies. Please see further description in “Product Development” below for a further description of the development of each indicated therapeutic.
(2) Each of these therapeutics have not undergone pre-clinical development. Please see further description in “Product Development” below for a further description of the development of each indicated therapeutic.
JMHO.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent CUBT News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/06/2024 09:31:41 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM